Table 1 Demographic and clinical data
Stable MCI (Aβ−) | Stable MCI (Aβ+) | MCI-AD (Aβ+) | MCI-other (Aβ−) | MCI-other (Aβ+) | |
|---|---|---|---|---|---|
Characteristics | |||||
N | 58 | 21 | 47 | 25 | 9 |
Age | 69 (8) | 69 (6) | 76 (7) | 73 (7) | 74 (6) |
Gender (% female) | 55% | 48% | 75% | 44% | 33% |
APOE genotype (% 1 or 2 ε4 alleles) | 29% | 81% | 81% | 44% | 78% |
CSF | |||||
Aβ42/40 | 0.10 (0.02) | 0.05 (0.01) | 0.05 (0.01) | 0.10 (0.02) | 0.06 (0.01) |
T-tau (pg/mL) | 68 (29) | 111 (72) | 148 (70) | 90 (43) | 75 (33) |
P-tau181 (pg/mL) | 26 (11) | 40 (21) | 54 (22) | 30 (12) | 33 (11) |
Plasma | |||||
GFAP baseline (pg/mL) | 36 (17) | 46 (25) | 67 (24) | 42 (16) | 52 (11) |
GFAP follow-up (pg/mL) | 43 (16) | 65 (41) | 94 (34) | 67 (27) | 78 (34) |